Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Glaukos: Clinical Trials & FDA Approval Profile

Glaukos (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (5 recruiting now), 7 completed protocols, and 4 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)201 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Glaukos
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)5 (5)
Completed vs Stopped Early7 / 1 (6.3%)
Median Closed Actual Enrollment201 participants
Physical Hospital Site Disclosure60.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals4 (2 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Glaukos Interactive Dossier, benchmark peers in Ophthalmology and Sensory, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI